News & Updates
Showing Multidisciplinary articles
Showing
Prednisolone ≥5 mg/day doubles risk of MACE in RA patients
In patients with rheumatoid arthritis (RA), use of systemic glucocorticoids (GC) is associated with a time- and dose-dependent increase in risk of major adverse cardiovascular events (MACE), a population-based real-world study has shown. On long-term follow-up, a prednisolone dose of ≥5 mg/day is associated with a doubled risk of MACE vs no GC use, and no safe duration of use is found for this daily GC dose.
Dapagliflozin cuts HbA1c in paediatric T2D
Dapagliflozin reduced HbA1c by 1.03 percentage points more than placebo in children and adolescents with type 2 diabetes (T2D), while saxagliptin showed no significant reduction vs placebo in the phase III T2NOW trial presented at EASD 2023.
First-line therapies for advanced NSCLC improve survival, QoL
Clinical trials on first-line therapies for advanced or metastatic nonsmall cell lung cancer (NSCLC) from 2010 to 2020 have reported better survival and a steady improvement in quality of life (QoL) among patients, according to the results of a systematic review.
Behavioural interventions improve screening colonoscopy uptake
Use of behavioural interventions, specifically multicomponent and patient navigation interventions, helps increase the uptake of colonoscopy for colorectal cancer (CRC) screening, reveals a study.
Finerenone confers cardiorenal benefits in Chinese CKD, T2D patients
In the subgroup analysis of the phase III FIGARO-DKD trial, the selective nonsteroidal mineralocorticoid receptor antagonist finerenone conferred cardiorenal benefits in Chinese patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). The findings were consistent with that observed in the overall cohort.
